Mutual of America Capital Management LLC Has $8.57 Million Position in Becton, Dickinson and Company (NYSE:BDX)

Mutual of America Capital Management LLC reduced its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.4% during the 3rd quarter, Holdings Channel.com reports. The fund owned 35,546 shares of the medical instruments supplier’s stock after selling 858 shares during the period. Mutual of America Capital Management LLC’s holdings in Becton, Dickinson and Company were worth $8,570,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in the business. Phraction Management LLC boosted its position in shares of Becton, Dickinson and Company by 3.0% during the 3rd quarter. Phraction Management LLC now owns 43,883 shares of the medical instruments supplier’s stock valued at $10,580,000 after acquiring an additional 1,276 shares in the last quarter. Vaughan Nelson Investment Management L.P. acquired a new position in Becton, Dickinson and Company in the third quarter valued at about $108,243,000. Comgest Global Investors S.A.S. boosted its position in Becton, Dickinson and Company by 43.9% in the third quarter. Comgest Global Investors S.A.S. now owns 11,255 shares of the medical instruments supplier’s stock valued at $2,714,000 after buying an additional 3,436 shares in the last quarter. Natixis Advisors LLC boosted its position in Becton, Dickinson and Company by 208.9% in the third quarter. Natixis Advisors LLC now owns 236,682 shares of the medical instruments supplier’s stock valued at $57,064,000 after buying an additional 160,073 shares in the last quarter. Finally, Northcape Wealth Management LLC boosted its position in Becton, Dickinson and Company by 1.5% in the third quarter. Northcape Wealth Management LLC now owns 9,694 shares of the medical instruments supplier’s stock valued at $2,337,000 after buying an additional 139 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Trading Down 0.4 %

Shares of NYSE BDX opened at $224.14 on Tuesday. The company’s 50 day simple moving average is $236.03 and its 200 day simple moving average is $234.89. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $249.89. The firm has a market capitalization of $64.79 billion, a P/E ratio of 37.73, a P/E/G ratio of 1.68 and a beta of 0.43. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.17 and a quick ratio of 0.74.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, beating the consensus estimate of $3.77 by $0.04. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The business had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same period in the prior year, the business posted $3.42 earnings per share. Becton, Dickinson and Company’s revenue was up 6.9% compared to the same quarter last year. On average, analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 31st. Investors of record on Monday, December 9th will be issued a $1.04 dividend. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. This represents a $4.16 annualized dividend and a yield of 1.86%. The ex-dividend date is Monday, December 9th. Becton, Dickinson and Company’s dividend payout ratio is currently 63.97%.

Analysts Set New Price Targets

BDX has been the topic of a number of recent analyst reports. Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and boosted their price target for the company from $255.00 to $275.00 in a research report on Tuesday, October 1st. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Stifel Nicolaus boosted their price target on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Evercore ISI upped their target price on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Finally, Raymond James decreased their price target on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research note on Friday, August 2nd. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Becton, Dickinson and Company has an average rating of “Buy” and a consensus price target of $283.00.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.